Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acasti Pharma (NQ: ACST )

0.4599 +0.0151 (+3.39%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 174,225
Open 0.4300
Bid (Size) 0.4500 (1)
Ask (Size) 0.4595 (1)
Prev. Close 0.4448
Today's Range 0.4250 - 0.4745
52wk Range 0.3400 - 1.350
Shares Outstanding 44,612,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
The biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning! 
Via InvestorPlace
Acasti Pharma Reports Third Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via Globe NewsWire

Performance

YTD
-8.51%
-8.51%
1 Month
-9.95%
-9.95%
3 Month
-8.20%
-8.20%
6 Month
-21.18%
-21.18%
1 Year
-62.30%
-62.30%

More News

Read More
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
From Acasti Pharma, Inc.
Via Globe NewsWire
Earnings Scheduled For February 14, 2023
Via Benzinga
Acasti Pharma's Earnings Outlook
Via Benzinga
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
From Acasti Pharma, Inc.
Via Globe NewsWire
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
Via Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
From Acasti Pharma, Inc.
Via Globe NewsWire
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
From Acasti Pharma, Inc.
Via Globe NewsWire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
From Acasti Pharma, Inc.
Via Globe NewsWire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
From Acasti Pharma, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Acasti Pharma Reports Second Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Acasti Pharma to Present at Q4 Investor Summit
From Acasti Pharma, Inc.
Via Globe NewsWire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
From Acasti Pharma, Inc.
Via Globe NewsWire
Acasti Pharma Inc. (NASDAQ:ACST) (TSX.V:ACST) Featured in Coverage of Investor Summit Group’s Q4 Event
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
121 Stocks That Hit Their 52-Week Low
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.